Journal: Atherosclerosis
Article Title: KUS121, a novel VCP modulator, attenuates atherosclerosis development by reducing ER stress and inhibiting glycolysis through the maintenance of ATP levels in endothelial cells.
doi: 10.1016/j.atherosclerosis.2025.119223
Figure Lengend Snippet: Fig. 1. KUS121 attenuated atherosclerosis progression in vivo. (A) Scheme of experimental protocol to assess the effect of KUS121 on atherosclerosis progression. (B) Representative images of HE staining in aortic sinuses and (C) quantitative analysis of plaque areas (n = 15 per group). Scale bar: 200 μm. (D) Representative images of en face ORO staining of whole thoracic aorta and (E) quantification of atherosclerotic lesions in aortic arches and descending aortas (n = 17 per group). Scale bar: 2 mm. (F) Representative images of CD68 staining in aortic sinuses and (G) quantification of CD68-positive areas in atherosclerotic plaques (n = 15 per group). Scale bar: 200 μm. (H) Quantification of the proportions of Chop-positive cells in different cell types and (I) representative images of Chop staining in the atherosclerotic plaques. Scale bar: 50 μm. All data is presented as mean ± SEM **p < 0.01, ***p < 0.001 by student’s t-test.
Article Snippet: Following antibodies were purchased and used for immunostaining: CD68 (FA-11, Bio-Rad, MCA1957, 1:200), Actin, α-Smooth Muscle (1A4, Sigma-Aldrich, F3777, 1:500), CD31 (2H8, Merck Millipore, MAB1398Z, 1:200), CD31 (MEC13.3, BD Pharmingen, 550274, 1:400), Icam1 (YN1/1.7.4, BioLegend, 116101, 1:200), Chop (F-168, Santa Cruz, sc-575, 1:100), NF-κB (C-20, Santa Cruz, sc-372, 1:200) and Cleaved Caspase-3 (Asp175, Cell signaling technology, #9661, 1:200).
Techniques: In Vivo, Staining